Phase 3 trial to further investigate the efficacy of TAS-102 in individuals
Phase three trial to further investigate the efficacy of TAS-102 in patients with mCRC refractory to common therapies . A total of 800 individuals with chemo-refractory mCRC were randomized (2:1…